HOME >> BIOLOGY >> NEWS
On target

In an upcoming Genes & Development paper, Dr. Christopher Counter and colleagues at the Duke University Medical Center have identified IL6 as a new target in the battle against Ras-induced cancers.

Ras is a key intracellular messenger protein that directs, among other things, cell growth and proliferation. Over-expression of the Ras oncogene, or of its growth-promoting pathway, is an integral step in the development of a number of human cancers, particularly pancreatic and lung cancer. Unfortunately, though, attempts to target Ras for inhibition in a clinical setting have proved unsuccessful.

"We knew Ras was really important for cancer, but time after time it defied attempts to be inhibited in the clinic. So we decided, why not go after something that you can make a drug against that Ras activates"" explains Dr. Counter. Dr. Counter and colleagues sought to identify other proteins that are secreted when Ras is activated, and evaluate them as potential therapeutic candidates. One factor, in particular, is receiving a lot attention.

Interleukin-6 (IL6) is an inflammatory cytokine (growth factor) that stimulates the immune system in response to injury. Dr. Counters team has demonstrated that Ras induces the secretion of IL6 in a number of different cell types. The scientists then showed that IL6 promotes tumorigenesis by encouraging new blood vessel growth.

Dr. Counter and colleagues were able to successfully fight tumor formation in a preclinical model by suppressing IL6 activity. While further research is needed to determine the effectiveness of IL6 targeted cancer therapies, these initial results are encouraging. "Targeting secreted proteins that Ras activates has opened the door to inhibit the oncogenic signal of Ras via druggable proteins," states Dr. Counter


'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
14-Jul-2007


Page: 1

Related biology news :

1. Huntingtons disease study shows animal models on target
2. New target for HIV/AIDS drugs and vaccine discovered
3. When off-target is right on
4. Genomic analysis uncovers new targets for HIV vaccine
5. Bulls-eye -- Programs targeting math, science teacher shortage may get boost
6. Scientists take next step in understanding potential target for ovarian cancer treatment
7. New way to target and kill antibiotic-resistant bacteria found
8. Weill Cornell team identifies potential new cancer drug target
9. CSHL scientists successfully target tumor microenvironment to stop cancer growth
10. Sleep deprivation affects airport baggage screeners ability to detect rare targets
11. Genomic signatures identify targeted therapies for lung cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/18/2019)... ... December 17, 2019 , ... Mitotech S.A, a Luxembourg-based clinical-stage ... its U.S. Phase 3 study VISTA-2 building on positive results of VISTA-1 clinical ... to severe Dry Eye Disease (DED). SkQ1 belongs to the class of cardiolipin ...
(Date:12/18/2019)... SEATTLE (PRWEB) , ... December 18, 2019 , ... ... higher education planning, has announced the Top 10 Master's in Biotechnology Degree Programs ... accredited colleges and universities in the nation. Each program is evaluated based on ...
(Date:12/14/2019)... ... 12, 2019 , ... Crop Enhancement Inc., an ... Jean Pougnier as chief business officer. Mr. Pougnier will lead the company’s efforts ... will position the company for maximum commercial success. As part of the expansion ...
Breaking Biology News(10 mins):
(Date:1/7/2020)... (PRWEB) , ... January 06, 2020 , ... ... a Digital World at The Fletcher School at Tufts University, is pleased to ... Foundation. The grant will be administered by Tufts University, and will help to ...
(Date:12/31/2019)... ... December 31, 2019 , ... Vici ... development lab in Maryland. Emphasis will be in expanding capabilities in ... Vici Health Sciences will be well positioned to meet the growing demand for ...
(Date:12/27/2019)... HARBOR TOWNSHIP, N.J. (PRWEB) , ... December 27, ... ... manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical ... first calendar year under new management . Following acquisition by CLJ Holdings ...
(Date:12/18/2019)... ... December 17, 2019 , ... Innovative Health, Inc. ... Electrophysiology (EP) devices since the company’s inception in 2016. This marks a record ... Johnson & Johnson company) have received 2 and 4 EP device clearances, respectively, ...
Breaking Biology Technology:
Cached News: